Congenital cytomegalovirus infectıon: Hematological evolutıon in newborn infants treated with gancıclovır

To verify the hematological evolution of newborns with congenital cytomegalovirus infection treated with Ganciclovir and two type of regimens.

Yöntem

 From January 1998 to December 2000, we studied 24 neonates with symptomatic congenital cytomegalovirus infection (CMV) that were admitted to the Neonatal lntensive Care Unit (NICU). The newborns were classified into two groups: 14 neonates were given an initial treatment course of 7.5 mg/Kg twice daily for three weeks, then a maintenance course of 10 mg/Kg three times a week for 3 months (Nigro 1994) (group A) and 10 neonates received 7.5 mg/Kg twice daily for three weeks (group B). Criteria for eligibility were: signs and symptoms compatible with a congenital infection from whom a specimen of urine and blood could be taken in the first 21 days of life.

Bulgular

In group A the CMV cultures and CMV DNA of specimens from eleven infants (80%) became sterile, in group B, five infants (50%) had negative CMV culture and CMV DNA results. The clinical features in group A inducled hepatomegaly (92.8%), splenomegaly (64.2%), anemia (57.1%), jaundice (55%) and petachial rash (55%). Hematological results are shown below: table 1 and table 2.

Sonuç

The authors concluded that the newborn infants that had been treated with Ganciclovir for a period of 3 months (group A) presented hematological evolution better than the group that was treated for a period of three weeks (group R) and the majority of newborn infants from group A showed CMV culture e CMV DNA negative shortly after the treatment. İt is safe to assume that patients submitted to a prolonged treatment with Ganciclovir respond far better than the ones treated over a shurter period.

Anahtar Kelimeler

-

	Dosya / Açıklama
	Tablo 1 Group Amedian values
	Tablo 2 Group B median values